Nektar Therapeutics (NKTR) Misses Q2 EPS by 258c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq retreat from record highs as yields and oil climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $39.15 -1.9%
EPS Growth %: -213.5%
Financial Fact:
Other income (expense), net: 332K
Today's EPS Names:
AEHR, VFS, CMTL, More
EPS Growth %: -213.5%
Financial Fact:
Other income (expense), net: 332K
Today's EPS Names:
AEHR, VFS, CMTL, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($2.78), $2.58 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $11.17 million versus the consensus estimate of $9.74 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deere & Co. (DE), Others Fall on Chatter of FTC Probe
- Applied Digital (APLD) October 9 weekly 24.50 and 25 calls active into quarter results
- Morgan Stanley selling pieces of $3 billion Royal Caribbean loan - Bloomberg
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
